Strikingly, JQ1 pre-treatment followed by Rituximab challenge led to significant and uniform increases in Rituximab-mediated killing of lymphoma cells presenting JQ1-sensitive MYC and CYCLON deregulation (Raji, B593 and SUDHL4), but not in lymphoma cells that showed JQ1-refractory CYCLON overexpression (HT, OCI-Ly3 and Ly10) (Fig 6C, D). This evidence concerns the gene CCDC86 and lymphoma.